Ventus Entered into an Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program to Treat Cardiometabolic Diseases
Shots:
- Ventus to receive $70M up front in cash incl. R&D funding & will also be eligible to receive an additional ~$633M in clinical, regulatory, and commercial milestones along with royalties
- Novo Nordisk to get an exclusive right globally to develop & commercialize Ventus’ NLRP3 inhibitor program for diseases, incl. NASH, CKD & other cardiometabolic conditions. Ventus also holds the right to develop NLRP3 inhibitors for systemic diseases incl. specific inflammatory & respiratory diseases and also gets the global rights to the brain-penetrant NLRP3 inhibitor program
- The collaboration combines Ventus’ NLRP3 inhibitor program with Novo Nordisk’s deep expertise across cardiometabolic diseases & provides clinical benefit to patients with a broad range of diseases
Ref: Ventus | Image: Novo Nordisk
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
